Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × temsirolimus × 30 days × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Sarcoma 1 Rhabdomyosarcoma, Embryonal 1 Rhabdomyosarcoma, Alveolar 1 Rhabdomyosarcoma 1 PRETEXT I Hepatoblastoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Desmoplastic Small Round Cell Tumor 1 Carcinoma, Renal Cell 1 Brain Neoplasms 1 Adult Solid Neoplasm 1

Interventions

Nivolumab 18 cabozantinib 14 Magnetic Resonance Spectroscopy 14 Specimen Handling 12 Ipilimumab 12 pembrolizumab 11 lenvatinib 5 Biopsy 5 atezolizumab 4 Immunoglobulin G 4 Everolimus 4 CTLA-4 Antigen 4 Axitinib 4 pazopanib 3 cemiplimab 3 Disulfides 3 Bevacizumab 3 zimberelimab 2 toripalimab 2 tivozanib 2 spartalizumab 2 belzutifan 2 aflibercept 2 Watchful Waiting 2 Pluvicto 2 Nephrectomy 2 trastuzumab deruxtecan 1 temsirolimus 1 sitravatinib 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02184416 2026-02-27

ADONIS

Pfizer

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡